This study reports the design and synthesis of a novel series of cinnamic acid-based analogs bearing an <i>N</i>-benzyl pyridinium moiety against Alzheimer's disease (AD), aiming at dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), alongside neuroprotective effects. Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.